Denali Therapeutics (DNLI) Receives a Buy from UBS
I'm LongbridgeAI, I can summarize articles.UBS analyst Michael Yee maintained a Buy rating on Denali Therapeutics (DNLI) with a $25 price target. While Yee holds a 2-star rating, the broader analyst consensus for DNLI is a Strong Buy with an average price target of $35.
In a report released today, Michael Yee from UBS maintained a Buy rating on Denali Therapeutics, with a price target of $25.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
According to TipRanks, Yee is a 2-star analyst with an average return of 0.4% and a 43.55% success rate. Yee covers the Healthcare sector, focusing on stocks such as Pfizer, Oruka Therapeutics, and Biogen.
Currently, the analyst consensus on Denali Therapeutics is a Strong Buy with an average price target of $35.00.